Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct-Dec;64(4):483-491.
doi: 10.47162/RJME.64.4.04.

Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals

Affiliations

Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals

Tudor Cuciureanu et al. Rom J Morphol Embryol. 2023 Oct-Dec.

Abstract

Introduction: Recent research points to a link between chronic hepatitis C virus (HCV) infection and cardiovascular disease, especially carotid atherosclerosis, and suggests that HCV clearance may impact cardiovascular outcomes.

Aim: To determine if viral eradication by the new oral direct-acting antiviral (DAA) agents has benefit regarding carotid atherosclerosis, peripheral artery disease (PAD), steatosis, and liver fibrosis.

Patients, materials and methods: We conducted a prospective study on 168 patients diagnosed with chronic HCV infection or HCV-related cirrhosis. They were all treated with DAAs, with sustained virological response (SVR). Laboratory data, vibration-controlled transient elastography (VCTE), carotid intima-media thickness (IMT) measurement, and ankle-brachial index (ABI) were recorded in all patients.

Results: We found an average IMT of 1.22±0.2 mm, with a variance range from 1.14±0.19 mm in the mild and moderate fibrosis (≤F2) group to 1.29±0.25 mm in the severe fibrosis (≥F3) group. Also, patients with severe fibrosis (≥F3) present a more critical decrease of IMT values, with the carotid thickness affecting only 18.2% of individuals in the follow-up period. At the baseline, the best values of ABI were recorded in patients having F1-F2 fibrosis stage (mean value 1.02±0.19). Instead, in the group with severe fibrosis, the average value of ABI was lower (0.91±0.16) at the baseline, with a significant increase at SVR evaluation (p<0.001).

Conclusions: Our research highlights the beneficial effect of viral eradication on both carotid atherosclerosis and PAD, especially in those with advanced fibrosis and cirrhosis.

PubMed Disclaimer

Conflict of interest statement

No conflict of interests is disclosed by the authors.

Figures

Figure 1
Figure 1
The atherosclerotic plaque and ultrasound measurement
Figure 2
Figure 2
– Assessment of carotid IMT. Measurement of the IMT of the CCA by high-resolution B-mode ultrasonography. IMT was measured by an automatic function algorithm as represented by the yellow and pink lines (the green line in the lumen of the CCA represents the reference value for the arterial wall echo gradient calculations). The yellow arrows fence the IMT thickness. CCA: Common carotid artery; IMT: Intima–media thickness
Figure 3
Figure 3
The calculation of IMT. CCA: Common carotid artery; ECA: External carotid artery; ICA: Internal carotid artery; IMT: Intima–media thickness
Figure 4
Figure 4
Correlation between CAP score post-SVR evaluation and IMT (A), ABI (B). ABI: Ankle–brachial index; CAP: Controlled attenuation parameter; IMT: Intima–media thickness; SVR: Sustained virological response.
Figure 5
Figure 5
Correlation between LSM score post-SVR evaluation and IMT (A), ABI (B). ABI: Ankle–brachial index; LSM: Liver stiffness measurements; IMT: Intima–media thickness; SVR: Sustained virological response

Similar articles

References

    1. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward) J Viral Hepat. 2014;21(Suppl 1):1–4. - PubMed
    1. Chang ML. Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol. 2016;22(4):1461–1476. - PMC - PubMed
    1. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–S173. - PubMed
    1. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–844. - PMC - PubMed
    1. Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure. Liver Int. 2018;38(Suppl 1):7–13. - PMC - PubMed

MeSH terms

Substances